Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 577 Carcinoma, Non-Small-Cell Lung 491 Ovarian Neoplasms 328 Lung Neoplasms 208 Fallopian Tube Neoplasms 153 Neoplasms 152 Stomach Neoplasms 128 Esophageal Neoplasms 127 Triple Negative Breast Neoplasms 125 Neoplasm Metastasis 121 Carcinoma, Ovarian Epithelial 115 Squamous Cell Carcinoma of Head and Neck 96 Endometrial Neoplasms 95 Uterine Cervical Neoplasms 80 Head and Neck Neoplasms 78 Esophageal Squamous Cell Carcinoma 77 Adenocarcinoma of Lung 49 Recurrence 48 Parkinson Disease 4, Autosomal Dominant Lewy Body 45 Melanoma 42 Carcinoma 42 Urinary Bladder Neoplasms 41 Adenocarcinoma Of Esophagus 36 Small Cell Lung Carcinoma 34 Carcinoma, Squamous Cell 34 Prostatic Neoplasms 32 Pancreatic Neoplasms 30 Breast Neoplasms, Male 28 Unspecified Adult Solid Tumor, Protocol Specific 27 Adenocarcinoma, Bronchiolo-Alveolar 26

Interventions

anlotinib 2 niraparib 1 afuresertib 1 Paclitaxel 1 PHI-101 1 Gemcitabine 1 ALT-803 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Platinum-resistant Ovarian Cancer × Paclitaxel × Clear all

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡